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We investigated the expression of membrane type-1 (MT1)-
MMP, MMP2, MMP9 and TIMP2 mRNAs and their roles in
ductal carcinoma in situ (DCIS) and T1 and T2 invasive ductal
carcinoma of the breast. We further compared these two types
of carcinomas for differences in microvessel density, and expres-
sion of angiogenic factors and CD44std. MT1-MMP, MMP2,
MMP9 and TIMP2 mRNA were expressed in both DCIS and
invasive ductal carcinomas. Expression rates of MT1-MMP,
MMP2, MMP9 and TIMP2 mRNAs were not statistically dif-
ferent between DCIS and invasive ductal carcinomas, nor did
they differ statistically when grouped by tumor size, histologic
grade or nuclear grade of invasive ductal carcinoma. Microvessel
density and expression of VEGF and TGF- 1 were not statisti β -
cally different between DCIS and invasive ductal carcinoma.
CD44std expression was significantly increased in DCIS
compared to invasive ductal carcinoma (p < 0.05) and it was
also significantly increased in lower clinical stage, histologic
grade and nuclear grade of invasive ductal carcinoma (p <
0.05). Axillary node metastasis was significantly correlated with
MT1-MMP mRNA, VEGF and TGF- 1 expression ( β p< 0.05)
and MT1-MMP mRNA was positively correlated with VEGF
expression and TIMP2 mRNA (p < 0.05). In summary, patterns
of MMP mRNA expression in DCIS and invasive ductal
carcinoma suggest that the invasive potential of breast carcinoma
is already achieved before morphologically overt invasive
growth is observed. As MT1-MMP mRNA expression is
significantly correlated with axillary nodal metastasis, it may be
useful as a prognostic indicator of invasive ductal carcinoma.
Considering the positive correlation of MT1-MMP mRNA and
TIMP2mRNA expression, our finding supports a role for TIMP2
in tumor growth, as well as the utility of CD44std as a pro-
gnostic indicator of breast cancer.
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INTRODUCTION
Degradation of basement membranes and ex-
tracellular matrix is an essential process in inva-
sion and metastasis in malignant tumors. MMP,
potent proteolytic enzymes are known to play key
roles in this process. Within the MMP families,
MMP-2 (gelatinase A, 72 kDa) and MMP-9 (gela-
tinase B, 92 kDa) cleave the type IV collagen and
gelatin, which are the principal structural compo-
nents of basement membrane.
1 Expression of
MMP2 and MMP9 has been reported in breast
cancer,
2-4 colon cancer,
5 skin tumors
6 and lung can-
cer
7 and their expression has been correlated with
local invasion by the tumor, lymph node metastasis
and survival rates.
2,3 Membrane type-1 (MT1) MMP
specifically activates the pro-gelatinase, MMP2 on
the tumor cell surface in vitro and binds with
TIMPs, hence, may have a role in controlling
MMP2 activity.
8 The cell surface adhesion mole-
cule, CD44, is also an important factor in invasion
and metastasis.
9-11 A recent report showed that
CD44 can localize active MMP9 protein to the
tumor cell surface where the CD44-MMP9 com-
plex induces TGF- 1 activation, which in turn β
promotes tumor invasion and angiogenesis.
12
To further understand their roles in breast can-
cer, we investigated the expression of MT1-MMP,
MMP2, MMP9 and TIMP2 mRNAs using mRNA in
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situ hybridization and microvessel density counts.
The expression of angiogenic factors and CD44std
as measured by immunohistochemical staining was
compared in ductal carcinoma in situ (DCIS) and
T1 and T2 invasive ductal carcinoma of the breast.
Further, we explored the roles of MT1-MMP,
MMP2, MMP9 and TIMP2 and the relationship
between MMP and TMP mRNA, CD44std, micro-
vessel density and angiogenic factors.
MATERIALS AND METHODS
Selection of patients and tumors studied
Primary breast cancer tissue obtained from 84
mastectomy patients was examined. The samples
included 21 cases of DCIS and 63 cases of T1 or
T2 invasive ductal carcinoma with the tumor size
of less than 5 cm. Patients with multiple foci of
disseminated tumor and a history of previous
axillary surgery on the same side of the body
were excluded.
Clinicopathological findings
The patients'age, tumor size, lymph node sta-
tus, clinical stage and histologic findings were
reviewed. Nuclear grades of DCIS and invasive
ductal carcinoma were grouped according to
Black's criteria.
13 Histologic grading of invasive
ductal carcinoma was classified according to the
modified Bloom and Richardson method.
14
Immunohistochemical staining
Immunohistochemical staining was performed
by the labeled streptavidin-biotin method using a
LSAB kit (DAKO, Carpinteria, CA, USA). One
representative section of the tissue was cut at 4 m μ
and placed on poly-L-lysine coated slides. The
slides were deparaffinized, rehydrated, immersed
in 10 mM sodium citrate (pH 6.0), and pretreated
in a microwave oven for 10 minutes, followed by
rinsing with TBS buffer (pH 7.6) for 10 minutes.
After blocking with 3% hydrogen peroxide and
normal goat serum, respectively, for 30 minutes
each, the slides were incubated at 4 overnight
with primary antibodies. The primary antibodies
employed were as follows: anti-CD44std (H-CAM,
mouse monoclonal antibody, Novocastra, New-
castle, UK, 1:50), anti-Factor VIII (clone F8/86,
mouse monoclonal antibody, DAKO, CA, USA,
1:50), anti-TGF- 1 (TB21, mouse antihuman anti β -
body, Serotec, Oxford, UK, 1:100), and anti-VEGF
(sc-152, rabbit polyclonal antibody, Santa Cruz,
CA, USA, 1:250). After incubation with the pri-
mary antibody, the slides were treated with, bio-
tinylated anti-mouse, rabbit IgG (DAKO) and a
complex of peroxidase conjugated streptavidin
(DAKO) in the order listed. The final reaction
products were visualized with 3-amino-9-ethyl-
carbazole and light hematoxylin counterstain.
Interpretation of immunohistochemical staining
Immunohistochemical staining for CD44std was
interpreted as positive when more than 10% of
tumor cells were stained along the cytoplasmic
membrane. A slide was scored as positive for
TGF- 1 and VEGF when more than 5% of tumor β
cells were stained in the cytoplasm of tumor cells.
Measurement of microvessel density
One representative tumor block was stained with
anti-Factor VIII antibody. Singular or clusters of
endothelial cells irrespective of whether they for-
med a lumen were counted as individual microves-
sels and blood vessels with thick muscular walls
were excluded. Microvessels were counted in the
highly vascular field of the tumor- stroma interface
or the central area of the tumor at × 200 mag-
nification and the average number of microvessels
obtained in three different fields was calculated.
In situ hybridization
In situ hybridization was done with the Inno
GenexTM universal ISH detection kit (InnoGenex,
San Ramon, CA, USA). The following probes were
labelled with FITC: MT1-MMP, MMP9, TIMP2
(human, Biognostik, Germany) DNAs and and a
MMP2 oligonucleotide (5'-TGG/GCT/ACG/GCG/
CGG/CGG/CGT/GGC-3'FITC, Genemed Syn-
thesis, Inc., South San Francisco, CA, USA.) Depa-
raffinized sections were blocked by washing in
sterile deionized water containing 0.2% RNase forBrief running Title: Expression of MMP and TIMP mRNAs in the Breast Carcinoma
Yonsei Med J Vol. 47, No. 3, 2006
5 minutes and pretreated with proteinase K at 3
7 for 15 minutes. Slides were heated in a micro-
wave for 2 minutes, cooled at room temperature
for 10 minutes, postfixed with 1% formalin/
RNase-free PBS for 10 minutes, and washed twice
with sterile deionized water containing 0.2%
RNase. Probes (MMP2 1:20, MMP9 1:15, TIMP2
1:15, MT1-MMP 1:15) were diluted into the manu-
facturer's hybridization solution and applied to the
slides. A coverglass was applied and slides were
heated to 80 for 5 minutes before hybridizing at
37 for 16 hours. Posthybridization washing was
done in 1 × and 0.1 × SSC solution containing
power block reagent for 5 minutes at room tem-
perature followed by biotinylated anti-probe
antibodies for 20 minutes at room temperature.
After washing with 1 × PBS, slides were treated
with streptavidin horseradish peroxidase conjugate
for 20 minutes, stained with aminoethyl carbazole
(AEC), and examined by light microscopy.
Positive controls were made with fluorescei-
nated poly (A) oligonucleotides and the negative
controls made with hybridization solution only
without probe. Determination of a positive reac-
tion was made when the nuclear and /or cyto-
plasmic staining of cells was more densely stained
than background.
Statistical analysis
Statistical analysis was performed using the
SPSS version 9.0 software program and a statis-
tical difference was considered significant when
the p value was 0.05 or less.
RESULTS
Expression of MMP and TIMP mRNA in DCIS
and invasive ductal carcinoma of the breast
MT1-MMP, MMP2, MMP9 and TIMP2 mRNAs
were expressed in 60%, 65%, 50%, and 35% of
DCIS and 46%, 58%, 44% and 38% of invasive
ductal carcinoma, respectively (Table 1). There
was no statistical difference in MMP and TIMP
mRNA expression levels between DCIS and
invasive ductal carcinoma. MMP mRNA expres-
sion using in situ hybridization was more intense
at the peripheral rim of tumor nests of the in-
vasive ductal carcinoma. Tumor cells were stained
in both nuclei and cytoplasm with the nuclei ex-
hibiting a stronger signal. Stromal cells were
occasionally stained, but less intensely than in
tumor cells (Fig. 1 and 2). A few normal ductal
cells were weakly stained.
CD44std expression in DCIS and invasive ductal
carcinoma of the breast
CD44std was expressed along the cytoplasmic
membrane in 76.2% of DCIS and 27.0% of invasive
Table 1. Expression of MMP and TIMP mRNAs, CD44std, and Angiogenic Factors in Ductal Carcinoma in Situ (DCIS)
and Invasive Ductal Carcinoma (IDC) of the Breast
DCIS (n = 21) IDC (n = 63) p value
MT1-MMP (+) 12 (60.0) 23 (46.0) NS
MMP2 (+) 13 (65.0) 29 (58.0) NS
MMP9 (+) 10 (50.0) 22 (44.0) NS
TIMP2 (+) 7 (35.0) 19 (38.0) NS
CD44std (+) 16 (76.2) 17 (27.0) 0.000*
Microvessel density (mean ± SD) 24.10 ± 7.18 29.26 ± 13.89 NS
VEGF (-) 0 (0) 6 (9.5)
NS
(+) 21 (100) 57 (90.5)
TGF- 1 β (-) 11 (52.4) 22 (34.9)
NS (+) 10 (47.6) 41 (65.1)
*p < 0.05; NS, not significant.Hee Jung Kim, et al.
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Fig. 3. CD44std immunohistochemical
staining shows strong positive along
the cytoplasmic membrane in DCIS
(A) and negative in invasive ductal
carcinoma (B)(× 200).
Fig. 2. mRNA in situ hybridization of
MT1-MMP (A), MMP2 (B), MMP9 (C),
TIMP2 (D) in DCIS (× 200).
Fig. 1. mRNA in situ hybridization of
MT1-MMP (A), MMP2 (B), MMP9 (C),
TIMP2 (D) in invasive ductal carci-
noma. Tumor cells were stained in
both nuclei and cytoplasm and their
nuclei were more strongly stained than
cytoplasm (× 200).
A B
C D
A B
C D
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ductal carcinoma, respectively. It was significantly
decreased in invasive ductal carcinoma compared
to DCIS (p < 0.05)(Table 1)(Fig. 3).
Microvessel density and expression of
angiogenic factors in DCIS and invasive ductal
carcinoma of the breast
Microvessel density within the tumor was 24.1
± 7.18 in DICS and 29.26 ± 13.89 in invasive
ductal carcinoma (Table 1). The microvessel den-
sity tended to increase in invasive ductal car-
cinoma compared to DCIS. The distribution of
microvessel in DCIS was conspicuous around the
basement membrane of tumor nests, which for-
med periductal cuffing. In contrast, microvessels
were usually distributed in the peripheral rather
than central zone of the tumor mass in invasive
ductal carcinoma. Expression of VEGF and TGF-β
1 was not statistically different between DCIS and
invasive ductal carcinoma.
Expression of MMP and TIMP mRNA according
to the clinical prognostic parameters of the
breast carcinoma
Expression levels of MT1-MMP, MMP2, MMP9
and TIMP2 mRNA did not significantly differ
Table 2. Expression levels of MMP and TIMP mRNAs and CD44std with Clinical Prognostic Parameters of the Breast
Carcinoma
No. of cases MT1-MMP (+) MMP2 (+) MMP9 (+) TIMP2 (+) CD44std (+)
Stage
0
1
2
p value
21
8
55
12 (60.0)
2 (25.0)
21 (50.0)
NS
13 (65.0)
3 (37.5)
26 (61.9)
NS
10 (50.0)
3 (37.5)
19 (45.5)
NS
7 (35.0)
2 (25.0)
17 (40.5)
NS
16 (76.2)
2 (25.0)
15 (27.3)
0.000*
T stage
Tis
T1
T2
p value
21
19
44
12 (60.0)
7 (43.8)
16 (47.1)
NS
13 (65.0)
7 (43.8)
22 (64.7)
NS
10 (50.0)
6 (37.5)
16 (47.1)
NS
7 (35.0)
6 (37.5)
13 (38.2)
NS
16 (76.2)
8 (42.1)
9 (20.5)
0.000*
HG
1
2
3
p value
13
25
25
6 (54.5)
10 (47.6)
7 (38.9)
NS
7 (63.6)
12 (57.1)
10 (55.6)
NS
4 (36.4)
10 (47.6)
8 (44.4)
NS
5 (45.5)
8 (38.1)
6 (33.3)
NS
6 (46.2)
4 (16.0)
7 (28.0)
NS
Black's NG
1 (High)
2 (Intermediate)
3 (Low)
p value
32
25
6
9 (39.1)
11 (47.8)
3 (75.0)
NS
12 (52.2)
15 (65.2)
2 (50.0)
NS
10 (43.5)
10 (43.5)
2 (50.0)
NS
7 (30.4)
9 (39.1)
3 (75.0)
NS
8 (25.0)
6 (24.0)
3 (50.0)
NS
Axillary nodal status
(-)
(+)
p value
23
40
5 (25.0)
18 (60.0)
0.015*
12 (60.0)
17 (56.7)
NS
7 (35.0)
15 (50.0)
NS
6 (30.0)
13 (43.3)
NS
5 (21.7)
12 (30.0)
NS
HG, histologic grade; NG, nuclear grade.
*p < 0.05; NS, not significant.Hee Jung Kim, et al.
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with clinical stage, tumor size, histologic grade or
nuclear grade of invasive ductal carcinoma. MT1-
MMP, MMP9 and TIMP2 mRNA were expressed
at higher levels in cases with axillary nodal metas-
tasis than those without axillary nodal metastasis,
with MT1-MMP mRNA expression significantly
correlated with axillary nodal metastasis (p <
0.05)(Table 2).
CD44std expression according to the clinical
prognostic parameters of the breast carcinoma
CD44std expression was significantly increased
in low clinical stage and small tumors (p < 0.05)
and was increased, but not significantly, in low
histologic and nuclear grade tumors. CD44std
expression was not significantly correlated with
axillary nodal status (Table 2).
Microvessel density and expression of angio-
genic factors according to the clinical prognostic
parameters of the breast carcinoma
Microvessel densities were not statistically dif-
ferent between clinical stages: 24.10 ± 7.18 in
stage 0, 23.60 ± 12.97 in stage 1 and 30.08 ± 14.15
in stage 2 (Table 3.) Microvessel density did not
increase significantly with tumor size (24.10 ±
7.18 in Tis, 26.20 ± 12.97 in T1 and 30.58 ± 14.20
in T2.) Microvessel density showed no significant
difference with the histologic grade, nuclear grade
and axillary nodal status of invasive ductal car-
cinoma.
TGF- 1 expression varied significantly with the β
clinical stage (p < 0.05)(Table 3). However, TGF- 1 β
expression did not differ significantly with tumor
size, histologic grade and nuclear grade of
invasive ductal carcinoma, On the other hand, the
rate of TGF- 1 expression was increased in the β
high histologic and nuclear grades.
VEGF expression did not vary significantly with
the clinical stage, tumor size, histologic grade or
nuclear grade of invasive ductal carcinoma (Table
3). However, expression of VEGF and TGF- 1 was β
significantly higher in cases with axillary nodal
metastasis compared to those without axillary
nodal metastasis (p < 0.05). Expression of VEGF
and TGF- 1 showed no significant correlation β
with microvessel density.
Relationship between MMP and TIMP mRNA,
CD44std, microvessel density, VEGF and TGF- 1 β
in invasive ductal carcinoma
MT1-MMP, MMP2, MMP9 and TIMP2 mRNA
levels were not significantly correlated with
microvessel density, TGF- 1, or CD44std. Among β
the MMPs, MT1-MMP mRNA was positively
correlated with VEGF and TIMP2 mRNA (p <
0.05) (Table 4).
DISCUSSION
This study was performed to demonstrate the
expression of MMP and TIMPs mRNA and to
determine their roles in noninvasive and invasive
ductal carcinoma of the breast. MMP and TIMP
mRNA expression in invasive mammary carci-
noma has been extensively studied. However,
MMP and TIMP mRNA expression levels in
noninvasive mammary carcinoma have not been
closely examined to date.
We compared the expression of MT1-MMP,
MMP2, MMP9 and TIMP2 mRNAs of DCIS with
that of invasive ductal carcinoma of breast. MT1-
MMP, MMP2, MMP9 and TIMP2 mRNAs were
expressed in both DCIS and invasive ductal
carcinoma. Moreover, their expression rate was
not significantly increased in invasive ductal car-
cinoma compared to DCIS. Brummer, et al.
15
reported MMP and TIMP mRNA expression using
in situ hybridization in benign and malignant
breast disease. In their study, normal breast and
fibrocystic disease showed rare MMP1 and MMP2
mRNA expression and noninvasive ductal carci-
nomas showed elevated MMP2 transcript levels in
peritumoral stromal cells without significant
MMP1 signals. Invasive ductal carcinoma dis-
played co-expression of MMP1 and MMP2 mRNA
in peritumoral stromal cells, mainly at the inva-
sion front. The MMP2 signal appeared to increase
gradually as the carcinomas progressed from non-
invasive to invasive states. Brummer's
15 and our
results of MMP mRNA expression in noninvasive
ductal carcinoma may suggest that an invasive
potential of breast carcinoma is already obtained
before morphologically overt invasive growth is
observed. We believe that further study is warTable 3. Microvessel Density and Expression of Angiogenic Factors with Clinical Prognostic Parameters of the Breast
Carcinoma
No. of cases
Microvessel density
(mean ± SD)
VEGF TGF- 1 β
(-) (+) (-) (+)
Stage
0 21 24.10 ± 7.18 0 (0) 21 (26.9) 11 (33.3) 10 (19.6)
1 8 23.60 ± 11.03 2 (33.3) 6 (7.7) 6 (18.2) 2 (3.9)
2 55 30.08 ± 14.15 4 (66.7) 51 (65.4) 16 (48.5) 39 (76.5)
p value NS NS 0.017*
T stage
Tis 21 24.10 ± 7.18 0 (0) 21 (26.9) 11 (33.3) 10 (19.6)
T1 19 30.58 ± 14.20 2 (33.3) 17 (29.8) 9 (27.3) 10 (19.6)
T2 44 26.20 ± 12.97 4 (66.7) 40 (51.3) 13 (39.4) 31 (60.8)
p value NS NS NS
HG
1 13 35.40 ± 20.36 1 (16.7) 12 (21.1) 4 (18.2) 9 (22.0)
2 25 29.07 ± 12.30 2 (33.3) 23 (40.4) 10 (45.5) 15 (36.6)
3 25 26.26 ± 10.48 3 (50.0) 22 (38.6) 8 (36.4) 17 (41.5)
p value NS NS NS
Black's NG
1 (High) 32 25.83 ± 9.39 3 (50.0) 29 (50.9) 10 (45.5) 22 (53.7)
2 (Intermediate) 25 33.11 ± 15.72 2 (33.3) 23 (40.4) 10 (45.5) 15 (36.6)
3 (Low) 6 31.48 ± 22.42 1 (16.7) 5 (8.8) 2 (9.1) 4 (9.8)
p value NS NS NS
Axillary nodal status
(-) 23 30.66 ± 12.09 5 (83.3) 18 (31.6) 13 (59.1) 10 (24.4)
(+) 40 28.45 ± 14.91 1 (16.7) 39 (68.4) 9 (40.9) 31 (75.6)
p value NS 0.012* 0.006*
HG, histologic grade; NG, nuclear grade.
*p < 0.05; NS, not significant.
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Table 4. Correlation of MT1-MMP mRNA and TIMP2 mRNA Expression Levels in Invasive Ductal Carcinoma
TIMP2 mRNA
p value
(-) (+)
MT1-MMP (-) 22 (71.0) 5 (26.3)
0.002*
MT1-MMP (+) 9 (29.0) 14 (73.7)
*p < 0.05.Hee Jung Kim, et al.
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ranted to determine MMP mRNA expression
levels according to histologic grades of DCIS in a
large population.
Our study using in situ hybridization showed
that MMP/TIMP mRNA expression was mainly
noted in tumor cells rather than in stromal cells
and displayed strong intensity at the interface
between tumor cell nests and the interstitial
stroma. Variation in the localization of MMPs has
been reported depending on the laboratory
methods or specific organ types. In breast tissue,
MMP expression using ELISA, northern blotting,
zymography and in situ hybridization has pri-
marily been observed in peritumoral interstitial
fibroblasts and not in tumor cells,
16-19 In contrast,
MMP protein expression using immunohisto-
chemical staining demonstrated that levels were
higher in tumor cells than in interstitial fibro-
blasts.
2,3,20,21 However, MMP mRNA and protein
levels in transitional carcinoma of the upper uri-
nary tract and MT1-mRNA in cervical carcinoma
and squamous carcinoma of lung were greater in
tumor cells than in stromal cells.
22-24 It is not clear
why these discrepancies are observed; variations
in laboratory methods or differences in organs
likely play a role. Regardless, these results suggest
a close relationship between tumor cells and
interstitial cells through a paracrine effect.
Our study showed no significant difference of
MT1-MMP, MMP2, MMP9 and TIMP2 mRNA
expression levels with stage, tumor size, histologic
grade or nuclear grade of invasive ductal carci-
noma. Only MT1-MMP mRNA expression was
significantly correlated with axillary nodal metas-
tasis. These results concur with Ueno's study
25
that MT1-MMP mRNA expression was signifi-
cantly correlated with lymph node metastasis and
distant metastasis and were not significantly
correlated with histologic grade. In our study,
MT1-MMP mRNA expression was not signifi-
cantly different between DCIS and invasive ductal
carcinoma. However, MT1-MMP mRNA expres-
sion was significantly correlated with axillary
nodal metastasis. From the above results, MT1-
MMP mRNA is considered to involve distant
metastasis rather than direct invasion of tumor.
MMPs are balanced with TIMPs, involved in
inhibition of MMP and regulation of their
activation in vitro. The delicate balance between
MMP and TIMP levels ultimately determines the
functions of MMP by protein degradation in
vitro.
26 Most of the MMP expression induced by
activated MMP accompanies increased expression
of one more TIMPs as a defense mechanism.
TIMP2 protein inhibits the activation of proMMP2
by forming a stable complex with activated
MT1-MMP, whereas low concentrations of TIMP2
can form a tertiary complex with MT1-MMP and
proMMP2 to eventually activate MMP2. Thus,
MT1-MMP combines with TIMP2 and influences
the activation state of MMP2. Earlier studies
reported that TIMPs inhibit tumor growth and
metastasis, but recent studies demonstrated that
TIMPs actually enhance tumor growth as well as
inhibit MMP. Adding to the controversy, TIMP
expression and the imbalance of MMP/TIMP
have been mentioned in recent studies to be poor
prognostic factors
27,28 or as important factors in
the tumor progression. Our study demonstrated
that MT1-MMP mRNA expression is positively
correlated with TIMP2 mRNA (p < 0.05) and that
a correlation between MT1-MMP mRNA and
MMP2 mRNA is not found. Considering the posi-
tive correlation of MT1-MMP mRNA and TIMP
2mRNA expression, our finding supports a role
for TIMP2 in tumor growth.
The cell surface adhesion molecule CD44 is an
important factor in invasion and metastasis.
However, the role of CD44 as a prognostic indica-
tor for breast carcinoma has been controvertial.
Lyzak, et al.
10 demonstrated that CD44std expres-
sion is negatively correlated with lymph node
metastasis and CD44v expression is not signifi-
cantly correlated with lymph node metastasis in
non-palpable T1a and T1b breast cancer. In con-
trast, some reports
11,29 showed CD44std expression
correlated with good prognosis and CD44v6
expression correlated with a poor prognostic
outcome, especially in low grade Hodgkin's
lymphoma, cervical carcinoma of stage I and IIB,
ovarian cancer and rectal cancer.
30-33 Our study
showed that CD44std expression was significantly
higher in DCIS (76.2%) than in invasive ductal
carcinoma (27%) and significantly higher in low
histologic (46.2%) and nuclear (50.0%) grade than
in high histologic (28.0%) and nuclear (25.0%)
grade invasive ductal carcinoma. The above
results suggest that CD44std could be used as aBrief running Title: Expression of MMP and TIMP mRNAs in the Breast Carcinoma
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prognostic indicator of breast cancer. Yu et al.
12 re-
cently showed that CD44 can localize active
MMP9 to the tumor cell surface with the CD44-
MMP9 complex providing TGF- 1 activation to β
promote tumor invasion and angiogenesis. We
failed to find a connection between CD44std,
MMP9 and TGF- 1. β
The intratumoral microvessel density was not
statistically different in invasive ductal carcinoma
and DCIS. However, microvessel density tended
to increase in cases with increased expression of
VEGF. In DCIS, the stromal microvessels actively
proliferated around the basement membrane of
tumor cell nests forming periductal cuffing. In
contrast, microvessels were prominent in the
peripheral tumor margin revealing more invasive
growth peripherally than in the center of the
tumor in invasive ductal carcinoma. We conclude
from these findings that invasive growth is
indirectly correlated with microvessel prolifera-
tion.
In summary, MT1-MMP, MMP2, MMP9 and
TIMP mRNAs, which are involved in stromal
invasion, are expressed in both DCIS and invasive
ductal carcinoma at similar levels. The MMP
mRNA expression levels suggest that an invasive
potential of breast carcinoma is already obtained
before morphologically overt invasive growth is
observed. As MT1-MMP mRNA expression is
significantly correlated with axillary nodal metas-
tasis, it might be considered as a significant pro-
gnostic indicator for invasive ductal carcinoma.
Considering the positive correlation between
MT1-MMP mRNA and TIMP2 mRNA expression,
our findings support a role for TIMP2 in tumor
growth. Further, CD44std could be used as a pro-
gnostic indicator of breast cancer. As our study is
limited by the small number of cases, a larger
study is warranted to confirm the prognostic
value of MMP/TIMPs in breast cancer and pre-
cancerous lesions.
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